Emerging biologic drugs for the treatment of rheumatoid arthritis

Francesco Puppo, Giuseppe Murdaca, Massimo Ghio, Francesco Indiveri

Research output: Contribution to journalArticlepeer-review


This article reviews the role of emerging biologic drugs for the treatment of rheumatoid arthritis (RA). Besides anti-tumor necrosis factor (TNF)-α and anti-interleukin (IL)-1 agents (Infliximab, Adalimumab, Etanercept and Anakinra) whose clinical efficacy is now established, new drugs have been proposed for the therapy of rheumatoid arthritis patients not responding to conventional treatments. These approaches include the blockade of B-cell activity with anti-CD20 monoclonal antibody (Rituximab) and the inhibition of T-cell activation with fusion protein CTLA4Ig. Moreover, promising results have been obtained in animal models utilizing suppressors of cytokine signaling (SOCS) and dominant-negative TNF variants to inactivate TNF signaling.

Original languageEnglish
Pages (from-to)537-541
Number of pages5
JournalAutoimmunity Reviews
Issue number8
Publication statusPublished - Nov 2005


  • Biologic drugs
  • CD20
  • CTLA4
  • Rheumatoid arthritis
  • Rituximab

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy


Dive into the research topics of 'Emerging biologic drugs for the treatment of rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this